Android app Apple app link

Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug

By Yahoo! Finance   |   1 month ago
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug

Sanofi and Teva Pharmaceuticals released new data from the Phase IIb RELIEVE UCCD trial of duvakitug for ulcerative colitis and Crohn's disease. The study showed higher rates of clinical remission with the antibody compared to a placebo, with positive safety results.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.